Goni Vijay G, Chhabra Rajesh, Gupta Ashok, Marwaha Neelam, Dhillon Mandeep S, Pebam Sudesh, Gopinathan Nirmal Raj, Bangalore Kantharajanna Shashidhar
Department of Orthopaedic Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Neurosurgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Asian Spine J. 2014 Aug;8(4):484-90. doi: 10.4184/asj.2014.8.4.484. Epub 2014 Aug 19.
Prospective case series.
To study the safety and feasibility of cotransplantation of bone marrow stem cells and autologous olfactory mucosa in chronic spinal cord injury.
Stem cell therapies are a novel method in the attempt to restitute heavily damaged tissues. We discuss our experience with this modality in postspinal cord injury paraplegics.
The study includes 9 dorsal spine injury patients with American Spinal Injury Association (ASIA) Impairment Scale (AIS) A neurological impairment who underwent de-tethering of the spinal cord followed by cotransplantation with bone marrow stem cells and an olfactory mucosal graft. Participants were evaluated at the baseline and at 6 monthly intervals. Safety and tolerability were evaluated through the monitoring for adverse events and magnetic resonance imaging evaluation. Efficacy assessment was done through neurological and functional outcome measures.
Surgery was tolerated well by all participants. No significant difference in the ASIA score was observed, although differences in the Functional Independence Measure and Modified Ashworth Scale were statistically significant. No significant complication was observed in any of our patients, except for neurogenic pain in one participant. The follow-up magnetic resonance imaging evaluation revealed an increase in the length of myelomalacia in seven participants.
The cotransplantation of bone marrow stem cells and olfactory mucosa is a safe, feasible and viable procedure in AIS A participants with thoracic level injuries, as assessed at the 24-month follow-up. No efficacy could be demonstrated. For application, further large-scale multicenter studies are needed.
前瞻性病例系列研究。
研究骨髓干细胞与自体嗅黏膜联合移植治疗慢性脊髓损伤的安全性和可行性。
干细胞疗法是一种用于修复严重受损组织的新方法。我们讨论了在脊髓损伤后截瘫患者中应用这种治疗方式的经验。
该研究纳入了9例美国脊髓损伤协会(ASIA)损伤分级(AIS)为A级神经功能障碍的胸段脊柱损伤患者,这些患者接受了脊髓松解术,随后进行了骨髓干细胞与嗅黏膜移植联合移植。在基线期及之后每隔6个月对参与者进行评估。通过监测不良事件和磁共振成像评估来评价安全性和耐受性。通过神经学和功能结局指标进行疗效评估。
所有参与者对手术耐受性良好。虽然功能独立性测量和改良Ashworth量表存在统计学显著差异,但ASIA评分未观察到显著差异。除一名参与者出现神经源性疼痛外,我们的患者均未观察到显著并发症。随访磁共振成像评估显示7名参与者脊髓软化长度增加。
在24个月随访评估中,骨髓干细胞与嗅黏膜联合移植对于AIS A级胸段损伤参与者是一种安全、可行且有效的手术方式。但未显示出疗效。如需应用,还需要进一步的大规模多中心研究。